Core Laboratories Inc. (CLB) Q4 2024 Earnings Conference Call Transcript
Core Laboratories Inc. (NYSE:CLB ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Josh Jayne - Daniel Energy Partners David Smith - Pickering Energy Partners Operator Good day, and welcome to the Core Laboratories' Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Core Laboratories (CLB) Misses Q4 Earnings and Revenue Estimates
Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.19 per share a year ago.
Core Laboratories to Post Q4 Earnings: Here's What to Expect
CLB is expected to report higher revenues from the year-ago period's level. However, despite this revenue growth, the company is expected to face increased operating expenses.
Core Laboratories (CLB) Reports Next Week: Wall Street Expects Earnings Growth
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Hold Strategy is Apt for Core Laboratories Stock Now
CLB benefits from strong international growth, high-margin projects and an efficient business model. However, stock underperformance, competition and U.S. market challenges pose risks.
Clinical Chemistry and Immunoassay Industry Forecast Report to 2028: Integrated and Scalable Core Lab Solutions Driving Transformational Growth
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health. While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables.
Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise?
CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility.
Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Is the Options Market Predicting a Spike in CORE LABS INC (CLB) Stock?
Investors need to pay close attention to CORE LABS INC (CLB) stock based on the movements in the options market lately.
Core Laboratories Inc. (CLB) Q3 2024 Earnings Call Transcript
Core Laboratories Inc. (NYSE:CLB ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants Sean Mitchell - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Lab Q3 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Core Laboratories' Q3 Earnings and Sales Beat Estimates
CLB expects Reservoir Description revenues of $87.5-$90.5 million and Production Enhancement revenues of $41-$45 million for the fourth quarter of 2024.
Core Laboratories (CLB) Q3 Earnings Match Estimates
Core Laboratories (CLB) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.
